U.S. markets closed

Supernus Pharma's ADHD drug meets main goal in late-stage trial

Dec 20 (Reuters) - Supernus Pharmaceuticals Inc said on Thursday its drug for attention deficit hyperactivity disorder met the main goal in a late-stage study testing in adolescents.

The company said it expects to announce data from the final late-stage trial of the drug, SPN-812, by the end of the first quarter of 2019, and submit a marketing application to the U.S. health regulator in the second half of 2019. (Reporting by Saumya Sibi Joseph in Bengaluru; Editing by Sriraj Kalluvila)